Skip to main content
. 2015 Jan 22;4(3):e994391. doi: 10.4161/2162402X.2014.994391

Figure 6.

Figure 6.

Combating trastuzumab-resistance by Tras-Permut CrossMab. (A), MTS assay examining the proliferation effects of Tras-Permut CrossMab (100 nmol/L) in both trastuzumab-sensitive and -resistant breast cancer cells (BT-474 and BT-474/TrasR) in the absence or presence of ErbB ligand (HRG). Results are shown as percentage of cell proliferation inhibition. Error bars, SD. Tras-Permut CrossMab was abbreviated as CrossMab. *p < 0.05. (B), Induction of cell death against trastuzumab-resistant breast cancer was assessed by staining with SYTOX® Red and FCM (In the absence of HER2 ligands, the concentration of antibodies is 10 μg/mL). Data are mean ± SD (n = 3). *p < 0.05. (C), ADCC activities of trastuzumab, pertuzumab L56TY, trastuzumab in combination with pertuzumab L56TY, or Tras-Permut CrossMab against both trastuzumab-sensitive and -resistant breast cancer. Mean ± SD values from four separate experiments. *p < 0.05. (D), tumor volume of trastuzumab-sensitive and -resistant BT-474 breast tumor xenografts after treatment with control IgG (10 mg/kg), trastuzumab (10 mg/kg), or Tras-Per CrossMab (10 mg/kg). Data are shown as means ± SEM. *p < 0.05, Mann–Whitney test.